Sec. 4. Continuing medical education and prescription drug monitoring program registration for prescribers
287 words·~1 min read·
/bill/116/hr/7701/ih/section-4·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Section 303 of the Controlled Substances Act ( 21 U.S.C. 823 ) is amended— by redesignating subsection
(k)as subsection (l); and by inserting after subsection
(j)the following: The Attorney General shall not register, or renew the registration of, a practitioner under subsection
(f)who is licensed under State law to prescribe controlled substances in schedule II, III, or IV, unless the practitioner submits to the Attorney General, for each such registration or renewal request, a written certification that— the practitioner has, during the 1-year period preceding the registration or renewal request, completed a training program described in paragraph (2); or the practitioner, during the applicable registration period, will not prescribe such controlled substances in amounts in excess of a 72-hour supply (for which no refill is available); and the practitioner has registered with the prescription drug monitoring program of the State in which the practitioner practices, if the State has such program. A training program described in this paragraph is a training program that— follows the best practices for pain management, as described in the Guideline for Prescribing Opioids for Chronic Pain as published by the Centers for Disease Control and Prevention in 2016, or any successor thereto, or the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics as published by the Food and Drug Administration in 2017, or any successor thereto; includes information on— recommending non-opioid and non-pharmacological therapy; establishing treatment goals and evaluating patient risks; prescribing the lowest dose and fewest number of pills considered effective; addictive and overdose risks of opioids; diagnosing and managing substance use disorders, including linking patients to evidence-based treatment; identifying narcotics-seeking behaviors; and using prescription drug monitoring programs; and is approved by the Secretary. .
Connectionstraces to 1
Traces to 1 document
U.S. Code
Citation graph
cites case law
Sec. 4
Continuing medical education and prescription drug monitoring program registration for prescribers
Cites 1Cited by 0 across 0 sources